Pure Global
NCT04619602

Inhaled Treatment for Bronchopulmonary Dysplasia

Pilot Study of an Inhaled Treatment for Bronchopulmonary Dysplasia
University Hospitals Cleveland Medical Center·Phase 1·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Bronchopulmonary Dysplasia
Drug/Device/Intervention
GSNO
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
University Hospitals Cleveland Medical Center
Location
Cleveland, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Jul 01, 2022
End date
Oct 01, 2024
Enrollment
20 participants
Primary outcome

Treatment Emergent Adverse Events

Summary

The primary objective of this study is to provide expanded access of S-nitrosylation therapy
 for the treatment of bronchopulmonary dysplasia

ICD-10 classifications
Bronchopulmonary dysplasia originating in the perinatal periodCongenital bronchomalaciaBronchopneumonia, unspecifiedOther congenital malformations of bronchusDiseases of bronchus, not elsewhere classified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04619602
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04619602 through Pure Global AI's free database. This Phase 1 trial is sponsored by University Hospitals Cleveland Medical Center and is currently Not yet recruiting. The study focuses on Bronchopulmonary Dysplasia. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.